- Home
- ATAT vs CDTX Comparison
ATAT vs CDTX Comparison
Compare ATAT & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATAT | CDTX |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.9B |
| IPO Year | 2022 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ATAT | CDTX |
|---|---|---|
| Price | $39.95 | $220.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $46.16 | ★ $128.75 |
| AVG Volume (30 Days) | ★ 1.1M | 880.9K |
| Earning Date | 11-25-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.14% | N/A |
| EPS Growth | ★ 25.36 | N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $1,276,315,178.00 | N/A |
| Revenue This Year | $37.82 | N/A |
| Revenue Next Year | $23.56 | N/A |
| P/E Ratio | $26.64 | ★ N/A |
| Revenue Growth | ★ 36.24 | N/A |
| 52 Week Low | $21.50 | $15.22 |
| 52 Week High | $43.17 | $221.20 |
Technical Indicators
Market Signals| Indicator | ATAT | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 84.47 |
| Support Level | $39.02 | $220.40 |
| Resistance Level | $42.99 | $221.00 |
| Average True Range (ATR) | 1.27 | 0.48 |
| MACD | -0.37 | -3.30 |
| Stochastic Oscillator | 25.06 | 85.50 |
Price Performance
Historical ComparisonAbout ATAT Atour Lifestyle Holdings Limited
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.